By AqVida GmbH
To get in touch with AqVida bringing advanced oncology offers to euroPLX Vienna, simply fill out the form below.
Subscribe to Supplier
AqVida bringing advanced oncology offers to euroPLX Vienna
Hamburg, Germany: AqVida, the German Oncology supplier, has developed a portfolio of medicines for treating the most common types of cancer and has recently stepped up production in its ultra-modern production facility, located in Dassow, Germany. AqVida will be available for business at euroPLX 64 in Vienna (29 – 30 May 2017).
AqVida will use the event as a platform to meet new potential business partners for licensing its impressive oncology portfolio. This includes oncology generic products like Imatinib, Oxaliplatin, Paclitaxel, Irinotecan, Docetaxel and Gemcitabine as well as its new generic generation like Sunitinib.
Advanced oncology generics
The company’s expertise in the development of generic oncology products has made AqVida a leading partner in the pharmaceutical industry, ensuring its place as one of the most important suppliers for oncology products, to multiple German and European pharmaceutical companies.
“We offer our portfolio to partner companies as in-licensing deals based upon MA transfers,” explained Jürgen Lehmberg, Commercial Director at AqVida, who will represent the company in Vienna.
“Our company has differentiated itself from the competition through short lead times, uncompromising quality standards and a high degree of supply flexibility – always maintaining off-the-shelf stock for our most in-demand products,” said Mr. Lehmberg.
“With our new manufacturing site, AqVida expects to increase this supply responsiveness even further. This aim, coupled with quality aspirations that extend beyond GMP requirements, has been the dominant theme guiding all the planning and construction of the Dassow facility”, Mr. Lehmberg added.
The novel engineering concept of the new facility involved designing a filling line with no format parts, based entirely on robotic vial handling. This novel approach not only drastically reduces set up times compared to a conventional filling line but also makes it possible to change vial format within batches with minimal interruption, using a closed isolator. The technology delivers measurable improvements in both efficiency and product safety.
Other innovations at Dassow include sustainable clean-room panels sourced from the UK-based company MRC provide a seamless finish to the clean room, as most of the furniture and coving is built into the wall panels themselves. AqVida is the first German company to use this high quality material in a new-build facility project.
High quality materials and advanced technology ensure that the site redefines the state of the art for aseptic filling of highly potent substances, where the complete process from compounding to innovative robotic filling is contained within isolators.
Additionally, through backward integration, AqVida is able to control the value within the entire chain; from generic development of products and related dossiers, through registration procedures, commercial production and finally supply of the products.
“When compared to the conventional German model of using third-party contract manufacturing facilities, AqVida, with its high degree of integration, truly offers a valid and sustainable alternative, with unrivalled advantages for all companies seeking high-quality oncology products, and this is a message we will be delivering very strongly at euroPLX 64 in Vienna,” says Wolfgang Heinze, CEO and founder of AqVida.
AqVida is a German oncology FDF manufacturer that is fully dedicated and specialized in the development, registration, manufacturing and distribution of finished dosage forms mainly for the oncology sector. It has developed a portfolio of medicines for treating the most common types of cancer.
AqVida’s expertise in generic oncology products has made the company a leading partner in the pharmaceutical industry.
AqVida works alongside some of the leading names in the oncology sector. In co-operation with its partners, AqVida has achieved substantial development and growth with its oncology portfolio.
AqVida is a pharmaceutical company with an impressive track record in fulfilling all client requirements from API sourcing through to EU market release for finished products. Teams of experts in development, regulatory affairs, patent issues and laboratory work bring skills and knowledge together to achieve optimum results for customers.
AqVida complies with all German and EU legal requirements for the pharmaceutical industry and is GMP certified by the German Health Authorities. As a European organization, AqVida has the knowledge and resources to provide regulatory support to meet the requirements of the complex and highly regulated EU market.
About euroPLX Vienna
Over two decades, the European Partner Licensing Exchange (euroPLX) cycle of networking conferences has facilitated continuous business development and pharma deals. Each cycle of information exchange between registrants seeking and offering business opportunities culminates in a conference, with three conferences held every year.
EuroPLX 64 is a two-day event opening May 29 at the Austria Trend Hotel Savoyen in Vienna. The conference attracts pharmaceutical business development decision makers, CEOs, owners, vice presidents, directors, and BD&L managers responsible for drug development, production and marketing from 150 companies worldwide.
A highly advanced online interaction and matchmaking system provides each company with up to 30 pre-arranged business meetings. Partnering scope ranges from prescription to OTC drugs, companion diagnostics, nutraceuticals, and medical devices: development, licensing, marketing, promotion, and distribution. The “Dynamic Partnering Focus” of this conference will show up on this page as soon as a sufficient number of collaboration interests is submitted.
The conference is organzed by RauCon with more information at: https://www.europlx.com/euroPLX-64